pre-IPO PHARMA

COMPANY OVERVIEW

Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease, inflammatory lung disease and arthritis.


LOCATION

  • Burnaby, British Columbia, Canada

  • THERAPEUTIC AREAS

  • Immunology
  • Inflammatory Disease
  • Oncology
  • Respiratory Disease

  • WEBSITE

    https://www.qubiologics.com/


    CAREER WEBSITE

    https://www.qubiologics.com/careers/is-qu-for-you/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 17, 2022

    Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly


    Sep 26, 2022

    Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer


    Jul 20, 2022

    Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead


    Mar 21, 2022

    Qu Biologics Closes USD$12M Equity Financing


    Jul 13, 2021

    Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress


    For More Press Releases


    Google Analytics Alternative